ADAPTIVE BIOTECHNOLOGIES CORPORATION Earnings Per Share, Basic and Diluted
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Earnings Per Share, Basic and Diluted of -$0.44 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.44.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.40.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.35.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.29.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION earnings per share, basic and diluted for fiscal 2021 was -$1.48.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION earnings per share, basic and diluted for fiscal 2020 was -$1.11.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION earnings per share, basic and diluted for fiscal 2019 was -$1.01.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION earnings per share, basic and diluted for fiscal 2018 was -$3.67.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$0.44 10-Q · filed 2022-05-04 | |||
| 2021-12-31 | -$1.48 10-K · filed 2022-02-15 | |||
| 2021-09-30 | -$0.40 10-Q · filed 2021-11-03 | -$1.04 10-Q · filed 2021-11-03 | ||
| 2021-06-30 | -$0.35 10-Q · filed 2021-08-04 | -$0.64 10-Q · filed 2021-08-04 | ||
| 2021-03-31 | -$0.29 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | -$0.33 derived: net income ÷ weighted average shares · filed 2022-02-15 | -$0.60 derived: net income ÷ weighted average shares · filed 2022-02-15 | -$0.86 derived: net income ÷ weighted average shares · filed 2022-02-15 | -$1.11 10-K · filed 2022-02-15 |
| 2020-09-30 | -$0.27 10-Q · filed 2021-11-03 | -$0.54 derived: net income ÷ weighted average shares · filed 2021-11-03 | -$0.79 10-Q · filed 2021-11-03 | -$0.95 derived: net income ÷ weighted average shares · filed 2022-02-15 |
| 2020-06-30 | -$0.26 10-Q · filed 2021-08-04 | -$0.51 10-Q · filed 2021-08-04 | -$0.68 derived: net income ÷ weighted average shares · filed 2022-02-15 | -$0.79 derived: net income ÷ weighted average shares · filed 2022-02-15 |
| 2020-03-31 | -$0.25 10-Q · filed 2021-05-05 | -$0.41 derived: net income ÷ weighted average shares · filed 2022-02-15 | -$0.53 derived: net income ÷ weighted average shares · filed 2022-02-15 | -$0.85 derived: net income ÷ weighted average shares · filed 2022-02-15 |
| 2019-12-31 | -$0.16 derived: net income ÷ weighted average shares · filed 2022-02-15 | -$0.28 derived: net income ÷ weighted average shares · filed 2022-02-15 | -$0.58 derived: net income ÷ weighted average shares · filed 2022-02-15 | -$1.01 10-K · filed 2022-02-15 |
| 2019-09-30 | -$0.11 10-Q · filed 2020-11-10 | -$0.44 derived: net income ÷ weighted average shares · filed 2020-11-10 | -$0.97 10-Q · filed 2020-11-10 | -$1.52 derived: net income ÷ weighted average shares · filed 2021-02-24 |
| 2019-06-30 | -$1.23 10-Q · filed 2020-08-10 | -$2.68 10-Q · filed 2020-08-10 | -$3.67 derived: net income ÷ weighted average shares · filed 2021-02-24 | -$4.34 derived: net income ÷ weighted average shares · filed 2021-02-24 |
| 2019-03-31 | -$1.45 10-Q · filed 2020-05-12 | -$2.44 derived: net income ÷ weighted average shares · filed 2021-02-24 | -$3.11 derived: net income ÷ weighted average shares · filed 2021-02-24 | -$4.12 derived: net income ÷ weighted average shares · filed 2021-02-24 |
| 2018-12-31 | -$1.00 derived: net income ÷ weighted average shares · filed 2021-02-24 | -$1.66 derived: net income ÷ weighted average shares · filed 2021-02-24 | -$2.66 derived: net income ÷ weighted average shares · filed 2021-02-24 | -$3.67 10-K · filed 2021-02-24 |
| 2018-09-30 | -$0.66 10-Q · filed 2019-11-12 | -$1.66 derived: net income ÷ weighted average shares · filed 2019-11-12 | -$2.67 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$1.01 10-Q · filed 2019-08-13 | -$2.02 10-Q · filed 2019-08-13 | ||
| 2017-12-31 | -$3.50 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |